Compare FTLF & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | GANX |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.6M | 159.2M |
| IPO Year | N/A | 2021 |
| Metric | FTLF | GANX |
|---|---|---|
| Price | $15.84 | $2.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $23.00 | $8.00 |
| AVG Volume (30 Days) | 17.2K | ★ 1.1M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $70,561,000.00 | N/A |
| Revenue This Year | $32.74 | N/A |
| Revenue Next Year | $50.36 | N/A |
| P/E Ratio | $23.18 | ★ N/A |
| Revenue Growth | ★ 12.44 | N/A |
| 52 Week Low | $9.83 | $1.41 |
| 52 Week High | $20.98 | $4.34 |
| Indicator | FTLF | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 38.61 |
| Support Level | $15.01 | $1.93 |
| Resistance Level | $16.90 | $2.07 |
| Average True Range (ATR) | 0.51 | 0.19 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 49.21 | 30.85 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.